These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37257190)

  • 21. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
    Geethakumari PR; Awan F
    Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Ibrutinib in the treatment of chronic lymphocytic leukemia and other B-cell malignancies].
    Wang M; Xu W; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):245-9. PubMed ID: 24598688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance.
    Blombery P; Thompson ER; Lew TE; Tiong IS; Bennett R; Cheah CY; Lewis KL; Handunnetti SM; Tang CPS; Roberts A; Seymour JF; Tam CS
    Blood Adv; 2022 Oct; 6(20):5589-5592. PubMed ID: 35901282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
    Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Noncatalytic Bruton's tyrosine kinase activates PLCγ
    Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
    J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors.
    Albitar A; Ma W; DeDios I; Estella J; Ahn I; Farooqui M; Wiestner A; Albitar M
    Oncotarget; 2017 Mar; 8(11):17936-17944. PubMed ID: 28212557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ibrutinib resistance in chronic lymphocytic leukemia.
    Furman RR; Cheng S; Lu P; Setty M; Perez AR; Guo A; Racchumi J; Xu G; Wu H; Ma J; Steggerda SM; Coleman M; Leslie C; Wang YL
    N Engl J Med; 2014 Jun; 370(24):2352-4. PubMed ID: 24869597
    [No Abstract]   [Full Text] [Related]  

  • 28. Ibrutinib for Chronic Lymphocytic Leukemia with
    Ahn IE; Tian X; Wiestner A
    N Engl J Med; 2020 Jul; 383(5):498-500. PubMed ID: 32726539
    [No Abstract]   [Full Text] [Related]  

  • 29. Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
    Zhang SQ; Smith SM; Zhang SY; Lynn Wang Y
    Br J Haematol; 2015 Aug; 170(4):445-56. PubMed ID: 25858358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BTK Inhibitors in Chronic Lymphocytic Leukemia.
    Gaballa S; Pinilla-Ibarz J
    Curr Hematol Malig Rep; 2021 Oct; 16(5):422-432. PubMed ID: 34599723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.
    Spaargaren M; de Rooij MF; Kater AP; Eldering E
    Oncogene; 2015 May; 34(19):2426-36. PubMed ID: 24954503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Molecular pathogenesis and treatment of chronic lymphocytic leukemia].
    Suzuki R
    Rinsho Ketsueki; 2021; 62(8):1085-1093. PubMed ID: 34497195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes.
    Hofland T; de Weerdt I; Ter Burg H; de Boer R; Tannheimer S; Tonino SH; Kater AP; Eldering E
    J Immunol; 2019 Oct; 203(8):2100-2109. PubMed ID: 31511358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful treatment with ribavirine for chronic hepatitis E in chronic lymphocytic leukemia treated with Ibrutinib.
    Boudin L; Patient M; Tsitsi Nding Tsogou P; Roméo E; Bladé JS; de Jauréguiberry JP
    Bull Cancer; 2019 Jan; 106(1):84-85. PubMed ID: 30579570
    [No Abstract]   [Full Text] [Related]  

  • 35. Targeted drugs in concert with chemo: opposites attract.
    Wendtner CM; Fischer K
    Blood; 2015 May; 125(19):2878-9. PubMed ID: 25953974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
    Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J
    J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).
    Woyach JA; Bojnik E; Ruppert AS; Stefanovski MR; Goettl VM; Smucker KA; Smith LL; Dubovsky JA; Towns WH; MacMurray J; Harrington BK; Davis ME; Gobessi S; Laurenti L; Chang BY; Buggy JJ; Efremov DG; Byrd JC; Johnson AJ
    Blood; 2014 Feb; 123(8):1207-13. PubMed ID: 24311722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Collectively Answering the Venetoclax BTK Inhibitor Sequencing Question in CLL.
    Rogers KA
    Clin Cancer Res; 2020 Jul; 26(14):3501-3502. PubMed ID: 32366672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.
    Tam CS
    Clin Adv Hematol Oncol; 2019 Jan; 17(1):32-34. PubMed ID: 30843894
    [No Abstract]   [Full Text] [Related]  

  • 40. Targeted therapies: ibrutinib resonates with us.
    Villanueva MT
    Nat Rev Clin Oncol; 2014 Jul; 11(7):380. PubMed ID: 24935013
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.